5-Azacytidine in chronic myelomonocytic leukemia: case report and review of literature

Main Article Content

Mariangela Greco
Marianna Criscuolo
Luana Fianchi
Livio Pagano
Maria Teresa Voso *
(*) Corresponding Author:
Maria Teresa Voso | mtvoso@rm.unicatt.it

Abstract

Hypomethylating drugs are useful in the management of Myelodysplastic syndromes, but  there are only few reports on chronic myelomonocycitic (CMML) leukemia patients. We describe our experience in 3 CMML patients treated with azacitidine. Two patients obtained partial response after 4 treatment cycles with only minor toxicity and are in continuous partial response, with stable peripheral blood counts, at 29 and 30 cycles from treatment start.


Downloads month by month

Downloads

Download data is not yet available.

Article Details

Author Biographies

Mariangela Greco

Greco M., Criscuolo M., Fianchi L., Fabiani E., Pagano L. and Voso MT

Maria Teresa Voso, Catholic University

Istituto di Ematologia, Assistant Professor